Vivesto 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Erik Kinnman

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	1.4yrs
CEO 소유권	n/a
경영진 평균 재임 기간	2.7yrs
이사회 평균 재임 기간	4.9yrs

최근 관리 업데이트

Recent updates

CEO

Erik Kinnman (66 yo)

1.4yrs

테뉴어

cMr. Erik Kinnman, M.D., Ph D., M.B.A., Assoc. Prof., serves as Chief Executive Officer at Vivesto AB since January 23, 2023.He had been Chief Executive Officer at Sprint Bioscience AB (publ) since March...

리더십 팀

이름	위치	테뉴어	보상	소유권
Erik Kinnman	Chief Executive Officer	1.4yrs	데이터 없음	데이터 없음
Robert Maiorana	Head of Accounting & Acting CFO	1.9yrs	데이터 없음	0.0037% SEK 5.9k
Urban Ekelund	IR Manager	no data	데이터 없음	데이터 없음
John Cosby	Head of Regulatory Affairs	18.4yrs	데이터 없음	데이터 없음
Dzianis Babrou	Head of Product Development	no data	데이터 없음	데이터 없음
Henrik Rönnberg	Chief Medical Officer of Animal Health	8.8yrs	데이터 없음	데이터 없음
Maria Hagberg	Head of Regulatory Affairs	5.2yrs	데이터 없음	데이터 없음
Heidi Ramstad	Chief Medical Officer	1.4yrs	데이터 없음	데이터 없음
Johanna Rostin	Chief Regulatory Officer	2.7yrs	데이터 없음	데이터 없음
Kia Bengtsson	Head of Clinical Development	2.7yrs	데이터 없음	데이터 없음
Teresa Zafra	Head of Preclinical Development & Clinical Operations	less than a year	데이터 없음	데이터 없음

2.7yrs

평균 재임 기간

57yo

평균 연령

경험이 풍부한 관리: 0N4A 의 관리팀은 경험 ( 2.7 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Göran Pettersson	Chairman of Business Advisory Board	4.9yrs	데이터 없음	데이터 없음
Hans Grönlund	Member of Scientific Advisory Board	4.9yrs	데이터 없음	데이터 없음
Mohammed Homman	Member of Business Advisory Board	4.9yrs	데이터 없음	데이터 없음
Jacob Kaluski	Member of Business Advisory Board	4.9yrs	데이터 없음	데이터 없음
Rolf Lewensohn	Chairman of Scientific Advisory Board	4.9yrs	데이터 없음	데이터 없음
Kerstin Strinnholm	Member of Business Advisory Board	5yrs	데이터 없음	데이터 없음
Pal Ryfors	Independent Director	2.1yrs	SEK 257.00k	데이터 없음
Hege Hellstrom	Member of Business Advisory Board & Independent Director	4.9yrs	SEK 361.00k	데이터 없음
Roger Tell	Independent Director	2.1yrs	SEK 218.00k	데이터 없음
Ola Winqvist	Member of Scientific Advisory Board	4.9yrs	데이터 없음	데이터 없음
Peter Zonabend	Chairman of the Board	5.3yrs	SEK 612.00k	0.13% SEK 213.8k

4.9yrs

평균 재임 기간

59yo

평균 연령

경험이 풍부한 이사회: 0N4A 의 이사회는 경험(평균 재직 기간 4.9 년)으로 간주됩니다.

Vivesto 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Vivesto AB (publ) Announces Composition of Nomination Committee

Vivesto AB Announces Appoints Erik Kinnman as CEO, Effective from January 23, 2023

Vivesto AB Announces Chief Executive Officer Changes, Effective No Later Than May 20, 2023

Vivesto AB Appoints Erik Kinnman as CEO

Vivesto AB Appoints Nomination Committee for 2023

Vivesto AB, Annual General Meeting, May 25, 2023

Recent updates

Vivesto's International Patent Application for XR-18 Receives Positive Decision

Vivesto AB's US Clinical Paccal Vet Trial Receives Approval to Start Patient Recruitment

Vivesto AB (publ) Announces Composition of Nomination Committee

Vivesto AB to Report Nine Months, 2024 Results on Nov 21, 2024

Vivesto AB Announces Early Termination of Patient Enrollment in the Investigator-Initiated Phase 1B Docetaxel Micellar Study

Vivesto AB Announces Appoints Erik Kinnman as CEO, Effective from January 23, 2023

Vivesto AB Announces Chief Executive Officer Changes, Effective No Later Than May 20, 2023

Vivesto AB Appoints Erik Kinnman as CEO

Vivesto AB Appoints Nomination Committee for 2023

Vivesto AB, Annual General Meeting, May 25, 2023

Vivesto AB Announces Resignation of Christer Nordstedt as Acting Ceo, Effective 30 November 2022

Second quarter 2022 earnings released

Vivesto AB Appoints Christer Nordstedt as Acting CEO

Vivesto AB Announces Chief Financial Officer Changes

Vivesto AB Announces CEO Francois Martelet Agrees on Ending the Employment Relationship, Effective July 21, 2022

First quarter 2022 earnings released: kr0.06 loss per share (vs kr0.10 loss in 1Q 2021)

Vivesto AB Announces Executive Changes

High number of new and inexperienced directors

Vivesto AB Appoints Daniel Tesfa as Chief Medical Officer

Oasmia Pharmaceutical AB announces step down of Fredrik Jarrsten as CFO

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Oasmia Pharmaceutical AB (Publ) Announces Update on Progress of Sakk Investigator-Initiated Phase 1B Trial of Docetaxel Micellar in Advanced Prostate Cancer

Oasmia Pharmaceutical Announces Progress on the Development of Its Next Generation XR-18 Drug Delivery Technology

High number of new and inexperienced directors

Independent Chairman recently bought kr53k worth of stock

Kazia Licenses Cantrixil, to Oasmia Pharmacetical AB

Fredrik JÃ¤rrsten to Join Oasmia Pharmaceutical AB (Publ) as CFO

Oasmia Pharmaceutical Appoints Dr. Heidi B. Ramstad as Chief Medical Officer

Oasmia Pharmaceutical AB (publ) Announces Proposed Class Action Settlement

Oasmia Pharmaceutical AB (publ) to Report Fiscal Year 2021 Results on Feb 24, 2022

Oasmia Pharmaceutical AB (publ) to Report Q3, 2021 Results on Nov 18, 2021

Oasmia Pharmaceutical AB (Publ) Announces Board Appointments

CEO

테뉴어

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령